logo-loader
viewPreveCeutical Medical Inc

PreveCeutical awarded default judgement on civil claim in British Columbia

The health sciences company received a judgement against JCN Capital Corp

judge's gavel
The company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) obtained a default judgement in a Supreme Court of British Columbia civil case, the company announced Monday.

The health sciences company received a default judgement against JCN Capital Corp in connection with a case brought by PreveCeutical alleging fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance.

READ: PreveCeutical gets default judgement in part of civil claim

The Vancouver-based company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements.

"We are pleased to have received this third default judgement as it demonstrates that PreveCeutical is actively pursuing this action," said PreveCeutical Chairman and CEO Stephen Van Deventer in a statement.

The amount of damages and costs awarded to PreveCeutical are still being assessed by the court.

The company continues to pursue other civil cases in the courts, according to a statement.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: PreveCeutical Medical Inc

Price: 0.0175 CAD

CSE:PREV
Market: CSE
Market Cap: $6.94 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc named herein, including the promotion by the Company of PreveCeutical Medical Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

1 week ago

2 min read